摘要
目的观察研究放疗联合希罗达与放疗联合顺铂治疗局部晚期食管癌的临床差异。方法随机抽取2015年4月到2017年8月100例局部晚期食管癌患者,将其分为对照组(n=50)与观察组(n=50),对照组患者予以放疗联合顺铂治疗,观察组患者予以放疗联合希罗达治疗,观察两组患者的临床治疗效果与不良反应的发生情况。结果观察组患者的临床总有效率为96.00%,对照组患者的临床总效率为98.00%,二者相比无明显差异,不具有统计学意义(P<0.05);但观察组患者的不良反应发生率明显低于对照组患者,差异明显,具有统计学意义(P<0.05)。结论放疗联合希罗达与放疗联合顺铂对于治疗局部晚期食管癌的疗效相近,但放疗联合希罗达将有效的降低患者的不良反应,对患者具有较高的安全性。
Objective to observe clinical difference of radiotherapy combined with xeloda and radiotherapy combined with cisplatin in treatment of local advanced esophageal cancer. Methods choose 100 cases locally advanced esophageal cancer patients from April 2015 to August 2017 randomly, divide them into control group(n=50) and observation group(n=50). Control group was treated with radiotherapy combined with cisplatin, and observation group with radiotherapy combined with xeloda. Observe clinical curative effect and adverse reactions of two groups. Results clinical total effective rate of observation group was 96.00%, that of control group was 98%, comparative difference between two groups showed no statistical significance(P<0.05); but adverse reaction rate of observation group was significantly lower than control group, difference showed statistical significance(P<0.05). Conclusion radiotherapy combined with xeloda, and radiotherapy combined with cisplatin has similar curative effect for local advanced esophageal cancer, but radiotherapy combined with xeloda can reduce patient's adverse reactions effectively, and has higher safety for patients, which has high clinical promotion value.
出处
《智慧健康》
2017年第18期126-128,共3页
Smart Healthcare
关键词
放疗联合希罗达
放疗联合顺铂
食管癌
临床差异
Radiotherapy combined with xeloda
Radiotherapy combined with cisplatin
Esophageal cancer
Clinical difference
